TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8129189

Group type: EXPERIMENTAL
Intervention: Picotamide, 300 mg three times a day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (three identical tablets each day)
Number of subjects: 20
Study: 2782273

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30, 60, or 90 mg once daily)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sustained-release propranolol (80, 160, or 240 mg once daily)
Number of subjects: 63
Study: 786662

Group type: EXPERIMENTAL
Intervention: Atenolol (Tenormin, ICI 66 082)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31189517

Group type: EXPERIMENTAL
Intervention: Oral semaglutide (14 mg once daily for 26 weeks)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 324
Study: 28784922

Group type: EXPERIMENTAL
Intervention: Fitbit One
Number of subjects: 21
Study: 25882235

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids derived from fish oil
Number of subjects: 131

Group type: COMPARATOR
Intervention: Oil-based placebo
Number of subjects: 131
Study: 23442271

Group type: EXPERIMENTAL
Intervention: Agility Training (AT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Traditional Military Physical Training (PT)
Number of subjects: 41
Study: 21870954

Group type: EXPERIMENTAL
Intervention: Outpatient programme using cognitive-behavioural techniques (experimental group, n=7)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified in size)
Number of subjects: 12
Study: 18298423

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 0.005% ointment (FP) twice daily during the acute phase and twice weekly during the maintenance phase
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo ointment twice weekly on consecutive days
Number of subjects: 90
Study: 17889314

Group type: EXPERIMENTAL
Intervention: Bupropion + nicotine patch
Number of subjects: 58

Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Discontinued cigarettes
Number of subjects: 58
Study: 15464333

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40 mg tadalafil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 60 mg tadalafil
Number of subjects: 60
Study: 11470383

Group type: EXPERIMENTAL
Intervention: Omeprazole (6-week course)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 9725545

Group type: EXPERIMENTAL
Intervention: [14C] irbesartan orally as a solution (50 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: [14C] irbesartan orally as a solution (150 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Irbesartan capsule (50 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: [14C] irbesartan as a 30‐minute intravenous infusion (50 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All routes of administration
Number of subjects: 18
Study: 8296814

Group type: EXPERIMENTAL
Intervention: High-intensity transcutaneous electrical nerve stimulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral naproxen (500 mg)
Number of subjects: 12
Study: 2690225

Group type: EXPERIMENTAL
Intervention: Combined modality treatment with 2x (COPP + ABVD) followed by 20 or 40 Gy EF radiation (HD1 protocol)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with 3x (COPP + ABVD) followed by consolidation therapy (20 Gy IF or further chemotherapy) or salvage therapy (40Gy or 4x CEVD chemotherapy) (HD3 protocol)
Number of subjects: 226
Study: 999494

Group type: EXPERIMENTAL
Intervention: Propranolol (20-40 mg every 4 hours, increased to 280-2320 mg per day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dexpropranolol (900 mg daily for 5 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (in 3 cases under double blind conditions)
Number of subjects: 6
Study: 29442231

Group type: EXPERIMENTAL
Intervention: Youth Aware of Mental Health (YAM) programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 26723137

Group type: EXPERIMENTAL
Intervention: Combined Individual and Group Intervention (CIGI)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Treatment-As-Usual (TAU)
Number of subjects: 99
Study: 24486835

Group type: EXPERIMENTAL
Intervention: N2O (60% inspired Nitrous oxide)
Number of subjects: 601

Group type: COMPARATOR
Intervention: AIR (40% oxygen)
Number of subjects: 601
Study: 22476175

Group type: EXPERIMENTAL
Intervention: Self-expandable metal stents (SEMS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Plastic multistent
Number of subjects: 31
Study: 21313952

Group type: EXPERIMENTAL
Intervention: In-group faces recognition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Out-group faces recognition
Number of subjects: 0
Study: 17921365

Group type: EXPERIMENTAL
Intervention: Price increase of low-energy-density (LED) foods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Price increase of high-energy-density (HED) foods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal BMI interaction with price increase of HED foods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal BMI interaction with price increase of LED foods
Number of subjects: 0
Study: 16118152

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) of the common extensor tendon
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) findings
Number of subjects: 22
Study: 12384358

Group type: EXPERIMENTAL
Intervention: Penicillin-nonsusceptible pneumococcus isolated from blood or cerebrospinal fluid
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pneumococcal isolates resistant to penicillin (MIC, > or =2.0 micro g/ml)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isolation of penicillin-nonsusceptible pneumococcus in children
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isolation of penicillin-nonsusceptible pneumococcus in adults with meningitis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multilocus sequence typing of invasive penicillin-resistant pneumococcus isolates
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Serotypes of penicillin-nonsusceptible pneumococci
Number of subjects: 100
Study: 10063913

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (30 ml)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ethyl alcohol (60 ml, 40% v/v)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bismuth subsalicylate (30 ml) pretreatment with ethyl alcohol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo pretreatment with ethyl alcohol
Number of subjects: 10
Study: 9063856

Group type: EXPERIMENTAL
Intervention: Low-energy extracorporeal shock wave therapy (ESWT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Simulated ESWT (placebo)
Number of subjects: 30
Study: 2043531

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 60
Study: 7180830

Group type: EXPERIMENTAL
Intervention: Dibromodulcitol, adriamycin, and tamoxifen (DAT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mitomycin-C and tamoxifen (MT)
Number of subjects: 32
Study: 30658774

Group type: EXPERIMENTAL
Intervention: Counterforce bracing
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo bracing
Number of subjects: 31
Study: 28371689

Group type: EXPERIMENTAL
Intervention: Take-home self-administered sublingual buprenorphine-naloxone weekly (mean dose, 22.7±5.7mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist control (no clinical intervention)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Take-home self-administered sublingual buprenorphine-naloxone weekly
Number of subjects: 50
Study: 26437830

Group type: EXPERIMENTAL
Intervention: 15 g freeze-dried wild blueberry (WBB) powder
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 30 g freeze-dried wild blueberry (WBB) powder
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 21
Study: 24599458

Group type: EXPERIMENTAL
Intervention: Attention (selective attention)
Number of subjects: 0
Study: 22293570

Group type: EXPERIMENTAL
Intervention: Propionate-rich sourdough bread
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 20
Study: 20797593

Group type: EXPERIMENTAL
Intervention: Addition of a second LV lead (test group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard biventricular stimulation (control group)
Number of subjects: 84
Study: 17923591

Group type: EXPERIMENTAL
Intervention: Combination ARB plus ACE inhibitor
Number of subjects: 17337
Study: 16195984

Group type: EXPERIMENTAL
Intervention: Critical swimming speed (CSS) at 92.7 +/- 2.6 % of maximal aerobic speed (MAS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Speed at maximal lactate steady state (S (MLSS)) at 88.3 +/- 2.9 % of MAS
Number of subjects: 8
Study: 11888584

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 560

Group type: COMPARATOR
Intervention: Ciclosporin microemulsion
Number of subjects: 560
Study: 9824351

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Cholangiopancreatography (MRCP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Number of subjects: 60
Study: 8527688

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg twice daily) + Ambroxol (30 mg thrice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ofloxacin (200 mg twice daily)
Number of subjects: 24
Study: 2109531

Group type: EXPERIMENTAL
Intervention: rIFN‐gamma at 0.01 mg/m2
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: rIFN‐gamma at 0.1 mg/m2
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: rIFN‐gamma at three dose levels (0.01 mg/m2, 0.05 mg/m2, 0.1 mg/m2)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: rIFN‐gamma at 0.05 mg/m2 for 6 weeks
Number of subjects: 22
Study: 7324924

Group type: EXPERIMENTAL
Intervention: Blood tests measuring ASAT and CK levels
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid tests measuring LD and HBD levels
Number of subjects: 57
Study: 31409183

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 30312135

Group type: EXPERIMENTAL
Intervention: Fucoidan 500 mg twice daily for 90 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo capsules twice daily for 90 days
Number of subjects: 72
Study: 28369198

Group type: EXPERIMENTAL
Intervention: Seasonal inactivated influenza vaccine (IIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25899425

Group type: EXPERIMENTAL
Intervention: Memantine therapy
Number of subjects: 13
Study: 24112444

Group type: EXPERIMENTAL
Intervention: Continuous endurance exercise in water
Number of subjects: 20

Group type: COMPARATOR
Intervention: High intensity intermittent endurance exercise in water
Number of subjects: 20
Study: 21857901

Group type: EXPERIMENTAL
Intervention: DNA (4 mg i.m. by Biojector) at 0, 1 and 2 months, followed by rAd5 (10(10) PU i.m. by needle/syringe) at 6 months
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 19394448

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention for breast cancer survivors
Number of subjects: 413

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 413
Study: 20664352

Group type: EXPERIMENTAL
Intervention: Oesomeprazole 40 mg once daily for 7 days
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 16313146

Group type: EXPERIMENTAL
Intervention: Active pressure-equalizing earplugs (JetEars)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo earplugs
Number of subjects: 27
Study: 12057730

Group type: EXPERIMENTAL
Intervention: Autologous endometrial coculture
Number of subjects: 208

Group type: COMPARATOR
Intervention: Conventional media
Number of subjects: 208
Study: 9857652

Group type: EXPERIMENTAL
Intervention: Procollagen III peptide concentration in bronchoalveolar lavage fluid in patients with allergic alveolitis
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Procollagen III peptide concentration in bronchoalveolar lavage fluid in patients with allergic alveolitis with DLCO < 60% pred
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Correlation between BAL lymphocytes number and procollagen III peptide concentration
Number of subjects: 23

Group type: COMPARATOR
Intervention: Procollagen III peptide concentration in bronchoalveolar lavage fluid in studied populations
Number of subjects: 23
Study: 7503088

Group type: EXPERIMENTAL
Intervention: Suppressive doses of levothyroxine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radioiodine, surgery, or ethanol injection for hot nodules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided fine-needle aspiration for larger nodules (>1.5 cm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitive thyrotropin assays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration biopsy
Number of subjects: 0
Study: 2152339

Group type: EXPERIMENTAL
Intervention: Methotrexate injected per anum (group 1, 19 patients)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Methotrexate administered intravenously (group 2, 17 patients)
Number of subjects: 36
Study: 349320

Group type: EXPERIMENTAL
Intervention: Elimination diet for four weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combined analysis of initial four-week diet period and four-week washout period
Number of subjects: 22

Group type: COMPARATOR
Intervention: Challenge with Yellow Dye No. 5 (tartrazine)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of children on diet
Number of subjects: 22
Study: 12160107

Group type: EXPERIMENTAL
Intervention: Alcohol (0.65 g alcohol/kg body weight)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 102

Group type: COMPARATOR
Intervention: Water control
Number of subjects: 102
Study: 31349723

Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 78
Study: 29249774

Group type: EXPERIMENTAL
Intervention: Lifestyle support program administered by pharmacists (brochures and healthy lifestyle advice using motivational interviewing methods) over a 12-week period
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 125
Study: 26500202

Group type: EXPERIMENTAL
Intervention: Task requiring self-control
Number of subjects: 111

Group type: COMPARATOR
Intervention: Task not requiring self-control
Number of subjects: 111
Study: 24928805

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: MAOBI
Number of subjects: 1620

Group type: COMPARATOR
Intervention: Dopamine agonists
Number of subjects: 1620
Study: 22591999

Group type: EXPERIMENTAL
Intervention: Serum IGF-I levels
Number of subjects: 776
Study: 20205258

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Number of subjects: 32
Study: 19094535

Group type: EXPERIMENTAL
Intervention: Tailored surgery group (limited gastric resection with D0-D1 lymphadenectomy)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional surgery group (standard radical gastrectomy with lymphadenectomy D2)
Number of subjects: 39
Study: 15759083

Group type: EXPERIMENTAL
Intervention: UV-B broadband
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: UV-B 311 nm narrowband
Number of subjects: 110

Group type: COMPARATOR
Intervention: Comparison of UV-B broadband to UV-B 311 nm narrowband
Number of subjects: 110
Study: 12375333

Group type: EXPERIMENTAL
Intervention: Once daily tramadol tablets
Number of subjects: 279

Group type: COMPARATOR
Intervention: Normal release tramadol capsules (50 mg) taken 3 or 4 times daily
Number of subjects: 279
Study: 9951568

Group type: EXPERIMENTAL
Intervention: Psychotherapy (weekly interpersonal psychotherapy)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Subjective sleep quality and REM activity measures
Number of subjects: 111
Study: 7800322

Group type: EXPERIMENTAL
Intervention: Conventional transvaginal sonography
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Transabdominal sonohysterography
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sonohysterographic evaluation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Hysteroscopy and transabdominal sonohysterography
Number of subjects: 52
Study: 2189979

Group type: EXPERIMENTAL
Intervention: Daily suction and débridement with intravenous mezlocillin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Daily suction and débridement with intravenous ceftazidime
Number of subjects: 51

Group type: COMPARATOR
Intervention: Daily suction and débridement without antibiotics (control)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All patients treated initially with antibiotics
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall recurrence rate
Number of subjects: 51
Study: 25707

Group type: EXPERIMENTAL
Intervention: Tienilic acid (250 mg to 500 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg to 100 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tienilic acid
Number of subjects: 19

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Tienilic acid and Hydrochlorothiazide
Number of subjects: 19
Study: 30431271

Group type: EXPERIMENTAL
Intervention: New strategy using residue type-specific dielectric constants and interaction entropy method
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard MM/GBSA method with normal mode approach
Number of subjects: 30
Study: 29967969

Group type: EXPERIMENTAL
Intervention: Fibrin Sealant Grifols (FS Grifols)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Surgicel (oxidized cellulose sheets)
Number of subjects: 325
Study: 26677829

Group type: EXPERIMENTAL
Intervention: Eccentric overload training (ECC) group performed 6 weeks of eccentric overload training (twice weekly, 4 sets of 7 repetitions in a Yoyo squat device) before the running intervention.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CONT)
Number of subjects: 20
Study: 24599421

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 665

Group type: COMPARATOR
Intervention: Selective estrogen-receptor modulators
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Time elapsed since diagnosis
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Smoking at diagnosis
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Overweight status at diagnosis
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Obese status at diagnosis
Number of subjects: 665
Study: 23363992

Group type: EXPERIMENTAL
Intervention: ZVF intervention (specifics not detailed in the abstract)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Extrafoveal regions in AMD patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Contrast sensitivity
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Extrafoveal increment blue cone threshold
Number of subjects: 54
Study: 20405093

Group type: EXPERIMENTAL
Intervention: STAR Workshop
Number of subjects: 0

Group type: COMPARATOR
Intervention: Web-based, self-guided e-book
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study: 17628705

Group type: EXPERIMENTAL
Intervention: Suction diathermy adenoidectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Curettage adenoidectomy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Suction diathermy with tonsillectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Curettage with tonsillectomy
Number of subjects: 100
Study: 16260662

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard operation
Number of subjects: 60
Study: 11829108

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 69
Study: 9551752

Group type: EXPERIMENTAL
Intervention: Mandibular advancement devices
Number of subjects: 15
Study: 7528129

Group type: EXPERIMENTAL
Intervention: β-blockers (general use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β-blockers (late use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β-blockers (heart failure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol and Atenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study: 2973571

Group type: EXPERIMENTAL
Intervention: 0.5 mg fenoterol hydrobromide
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.25 mg ipratropium bromide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 14
Study: 30100558

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT) with cilostazol
Number of subjects: 183

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAT)
Number of subjects: 183
Study: 27787471

Group type: EXPERIMENTAL
Intervention: Plyometric training (20 min·d, twice a week, during 12 weeks)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study: 23059702

Group type: EXPERIMENTAL
Intervention: Articulated delivery arm system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Straight delivery arm system
Number of subjects: 30
Study: 24267484

Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 80